BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Nfocus Neuromedical, Inc. Obtains CE Approval for New Vascular Reconstruction Device


8/12/2009 6:57:14 AM

Bookmark and Share

PALO ALTO, Calif., Aug. 12 /PRNewswire/ -- Nfocus Neuromedical Inc. announced today that its CardioVasc Advantage(TM) Vascular Reconstruction Device has been granted CE Mark approval by the European Notified Body, G-Med.

"The technology of the Advantage VRD is an important demonstration of Nfocus design talent and teamwork," noted company Chairman, Eric P. Milledge. "The technical platform behind this device will pave the way for future Nfocus neurovascular products currently in development."

The CardioVasc Advantage(TM) Vascular Reconstruction Device has been cleared in Europe for the treatment of coronary artery perforations, aneurysms and saphenous vein graft lesions. Today, these critical pathologies are most frequently treated through less-invasive endovascular procedures. The Advantage VRD was designed to provide clinical benefits in these exacting procedures performed in small vessels.

"The Advantage VRD is a significant advance over previous small-vessel stent-grafts," said Martin S. Dieck, President and CEO.

"The Advantage VRD has greatly improved flexibility and a smaller crossing profile when compared to competitive devices. The European CE Mark approval gives Nfocus the ability to market this advanced system for the treatment of serious coronary vascular indications. The device is capable of attaining more distal placement with less vessel trauma due to its innovative design."

About Nfocus Neuromedical, Inc.

Nfocus is positioning itself to be the world-wide leader in the development of next-generation endovascular neurosurgery solutions (surgery through less-invasive catheter devices) . Backed by premier venture investors, the Company's primary mission is developing revolutionary systems to treat neurovascular disease, including brain aneurysms, that are simple, safe, cost-effective and curative.

To learn more about the Nfocus Neuromedical development programs focused on providing faster, simpler and more permanent treatment of vascular diseases of the brain and spine, please visit the Nfocus website: www.nfocusneuro.com.

For more information about aneurysms and hemorrhagic stroke see: www.strokeassociation.org and www.snisonline.org


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->